Publications

  1. Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Oct 6 Epub 2020 Oct 06
    View PubMed
  2. Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy. Eur J Cancer. 2020 Sep; 137:1-9 Epub 2020 July 23
    View PubMed
  3. Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Jul 23 Epub 2020 July 23
    View PubMed
  4. Monga V, Skubitz KM, Maliske S, Mott SL, Dietz H, Hirbe AC, Van Tine BA, Oppelt P, Okuno S, Robinson S, O'Connor M, Seetharam M, Attia S, Charlson J, Agulnik M, Milhem M. A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. Cancers (Basel). 2020 Jul 11; 12 (7) Epub 2020 July 11
    View PubMed
  5. Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schoffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul; 21 (7):923-934 Epub 2020 June 05
    View PubMed
  6. Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 Jul; 9 (13):4593-4602 Epub 2020 May 06
    View PubMed
  7. Jacob S, Carroll ND, El-Sayed Ahmed MM, Attia S, Jim Zhai Q, Bower SP, Makey IA. Thoracoabdominal resection of giant malignant esophageal solitary fibrous tumor. J Surg Case Rep. 2020 Jul; 2020 (7):rjaa152 Epub 2020 July 14
    View PubMed
  8. Younger E, Ballman K, Lu Y, Papai Z, Van Tine BA, Attia S, Schoffski P, Reinke D, Tap WD, Jones RL. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. J Geriatr Oncol. 2020 Apr; 11 (3):463-469 Epub 2019 May 22
    View PubMed
  9. Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 Mar 15; 26 (6):1258-1266 Epub 2020 Jan 03
    View PubMed
  10. Alman B, Attia S, Baumgarten C, Benson C, Blay JY, Bonvalot S, Breuing J, Cardona K, Casali PG, van F, Colombo C, Dei AP, Dileo P, Ferrari A, Fiore M, Frezza AM, Garcia J, Gladdy R, Gounder M, Gronchi A, Haas R, Hackett S, Haller F, Hohenberger P, Husson O, Jones RL, Judson I, Kasper B, Kawai A, Kogosov V, Lazar AJ, Maki R, Mathes T, Messiou C, Navid F, Nishida Y, Palassini E, Penel N, Pollock R, Pieper D, Portnoy M, Raut CP, Roets E, Sandrucci S, Sbaraglia M, Stacchiotti S, Thornton KA, van W, van K, van WJ, Villalobos, Wagner AJ, Wardelmann E, Wartenberg M, Watson S, Weiss A, Zafiropoulos N, Desmoid Tumor Working Group . The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer.. 2020; 127:96-107.
  11. Van Tine BA, Govindarajan R, Attia S, Somaiah N, Barker SS, Shahir A, Barrett E, Lee P, Wacheck V, Ramage SC, Tap WD. Incidence and Management of Olaratumab Infusion-Related Reactions. J Oncol Pract. 2019 Nov; 15 (11):e925-e933 Epub 2019 July 03
    View PubMed
  12. Jones RL, Chawla SP, Attia S, Schoffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 Jul 15; 125 (14):2445-2454 Epub 2019 Apr 29
    View PubMed
  13. Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1; 37 (16):1424-1431 Epub 2019 Apr 23
    View PubMed
  14. Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, Pishvaian MJ, Riedel RF, Sabagh T, Tap WD, Horvat N, Basch E, Schwartz LH, Maki RG, Agaram NP, Lefkowitz RA, Mazaheri Y, Yamashita R, Wright JJ, Dueck AC, Schwartz GK. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018 Dec 20; 379 (25):2417-2428
    View PubMed
  15. van Tine BA, Mohindra N, Milhem M, Attia S, Robinson SI, Rademaker A, Okuno SH, Agulnik M. A phase II study of pazopanib with oral topotecan in patients with metastatic osteosarcoma. Ann Oncol. 2018 Oct; 29 Suppl 8:viii579
    View PubMed
  16. Stacchiotti S, Blay JY, Jones RL, Demetri GDD, Mir O, Italiano A, Thomas D, Chen TW, Schoffski P, Gil T, Jahan T, Cote G, Ratan R, Attia S, Roche M, Daigle S, Sapir I, Clawson A, Gounder M. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii580
    View PubMed
  17. Gounder M, Schoffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers ET, Italiano A, Gupta A, Agulnik M, Attia S, Jones RL, van Tine BA, Demetri GDD, Roche M, Sapir I, Daigle S, Clawson A, Stacchiotti S. A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults: Epithelioid sarcoma cohort (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii581-viii582
    View PubMed
  18. Agulnik M, van Tine BA, Attia S, Rademaker A, Milhem M, Okuno SH. Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma. Ann Oncol. 2018 Oct; 29 Suppl 8:viii592
    View PubMed
  19. Daigle S, Stacchiotti S, Schoffski P, Villalobos V, Cote G, Chugh R, Chen TW, Jahan T, Loggers ET, Italiano A, Gupta A, Agulnik M, Attia S, Jones RL, van Tine BA, Demetri GDD, Clawson A, Roche M, Blakemore S, Gounder M. Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Ann Oncol. 2018 Oct; 29 Suppl 8:viii670
    View PubMed
  20. Agulnik M, Attia S. Growing Role of Regorafenib in the Treatment of Patients with Sarcoma. Target Oncol. 2018 Aug; 13 (4):417-422
    View PubMed
  21. Bagaria SP, Chang YH, Gray RJ, Ashman JB, Attia S, Wasif N. Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both? Sarcoma. 2018; 2018:8141056 Epub 2018 Apr 03
    View PubMed
  22. Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW. Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Front Oncol. 2018; 8:71 Epub 2018 Mar 22
    View PubMed
  23. Bagaria SP, Neville M, Gray RJ, Gabriel E, Ashman JB, Attia S, Wasif N. The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions. Sarcoma. 2018; 2018:3056562 Epub 2018 July 24
    View PubMed
  24. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov; 18 (11):1493-1501 Epub 2017 Oct 04
    View PubMed
  25. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schoffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug; 18 (8):1089-1103 Epub 2017 June 23
    View PubMed
  26. Davila JI, Starr JS, Attia S, Wang C, Knudson RA, Necela BM, Sarangi V, Sun Z, Ren Y, Casler JD, Menke DM, Oliver GR, Joseph RW, Copland JA, Parker AS, Kocher JA, Thompson EA, Smallridge RC, Asmann YW. Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell Sarcoma. Rare Tumors. 2017 Jul 3; 9 (2):6834 Epub 2017 Sept 15
    View PubMed
  27. Jagadesh N, Miller DH, Schenk W, Attia S, Sherman CE, Cortese C, May BC, Miller RC. Recurrent myxoinflammatory fibroblastic sarcoma: a case report. Clin Case Rep. 2017 Jun; 5 (6):871-875 Epub 2017 Apr 20
    View PubMed
  28. Garner HW, Bestic JM, Peterson JJ, Attia S, Wessell DE. Preoperative radioactive seed localization of nonpalpable soft tissue masses: an established localization technique with a new application. Skeletal Radiol. 2017 Feb; 46 (2):209-216 Epub 2016 Nov 24
    View PubMed
  29. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhan's Cell Sarcoma: Two Case Reports. Rare Tumors. 2016 Mar 21; 8 (1):6140 Epub 2016 Apr 06
    View PubMed
  30. Brett CL, Miller DH, Jiang L, Wolfsen HC, Attia S, Hintenlang L, Jagadesh N, Miller RC. Dedifferentiated liposarcoma of the esophagus: A case report and selected review of the literature Rare Tumors. 2016; 8: (4)201-2.
  31. Kaleem TA, Schild MH, Miller D, Jha A, Cortese C, Attia S, Miller RC. Langerhan’s cell sarcoma: Two case reports Rare Tumors. 2016; 8: (1)17-9.
  32. Bagaria SP, Wagie AE, Gray RJ, Pockaj BA, Attia S, Habermann EB, Wasif N. Validation of a Soft Tissue Sarcoma Nomogram Using a National Cancer Registry. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S398-403 Epub 2015 Sept 09
    View PubMed
  33. Starr JS, Attia S, Joseph RW, Menke D, Casler J, Smallridge RC. Follicular Dendritic Cell Sarcoma Presenting As a Thyroid Mass. J Clin Oncol. 2015 Jun 10; 33: (17)e74-6.
    View PubMed
  34. Sood N, Swaika A, Hanooshi B, Waldorf J, Peterson J, Wu K, Attia S, Dinh TA. High Grade Leiomyosarcoma Mimicking a Recurrent Angiomyxoma in the Perineum. Rare Tumors. 2015 May 5; 7 (2):5875 Epub 2015 May 19
    View PubMed
  35. Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Bagaria SP, Jones RL, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors. 2015 May 5; 7 (2):5992 Epub 2015 May 21
    View PubMed
  36. Jaime Davila, Yan Asmann, Jason Starr, Steven Attia, Chen Wang, Ryan Knudson, Brian Necela, Vivekananda Sarangi, Gavin R Oliver, Zhifu Sun, Raymond Moore, Xue Wang, John Casler, David Menke, Richard Joseph, John A Copland, Alexander Parker, Jean Pierre, Kocher, Aubrey Thompson, Robert C Smallridge. Extensive genomic profiling of a rare extranodal-follicular dendritic cell sarcoma reveals mutations in drug targetable genes, extensive copy number changes and novel fusions. JAMA. May 2015 (submitted).
  37. Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Sherman C, Kozak KR, Cortese CM, McFarland T, Trent JC, Maki RG. Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma. Rare Tumors. 2015; 7(2):86-8.
  38. Noriega-Iriondo MF, Colon-Otero G, Kipp BR, Copland JA, Ferber MJ, Marlow LA, Roberts ME, Robertson MW, Dinh TA, Attia S, Geiger XJ, Riegert-Johnson DL. High-grade endometrial stromal sarcoma as the initial presentation of an adult patient with Peutz-Jeghers Syndrome: a case report. Hered Cancer Clin Pract. 2015; 13 (1):6 Epub 2015 Jan 23
    View PubMed
  39. Conley AP, Koplin S, Caracciollo JT, Reed DR, Webber NP, Attia S. Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor. J Clin Oncol. 2014 Nov 10; 32(32):e107-10. Epub 2014 Feb 18.
    View PubMed
  40. Carey K, Bestic J, Attia S, Cortese C, Jain M. Diffuse skeletal muscle metastases from sacral chordoma. Skeletal Radiol. 2014 Jul; 43 (7):985-9 Epub 2014 Jan 10
    View PubMed
  41. Islam R, Rafiullah A, Thogarucheeti B, Hague N, Attia S. A case of biphasic sarcoma with lung and breast metastasis responding to pazopanib. Journal of Clinical Oncology and Research. 2014 May 5; 2(5):1037.
  42. Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs. 2013 Dec; 31(6):1539-46. Epub 2013 Oct 10.
    View PubMed
  43. Buehler D, Rice SR, Moody JS, Rush P, Hafez GR, Attia S, Longley BJ, Kozak KR. Angiosarcoma Outcomes and Prognostic Factors: A 25-Year Single Institution Experience. Am J Clin Oncol. 2013 Feb 20.
    View PubMed
  44. Cornett D, Benson M, Attia S, Weiss J, Gopal D. Metastatic Kaposi's Sarcoma with Perirectal Involvement Diagnosed with Endoscopic Ultrasound-Guided EchoBrush Cytology Sampling. Case Rep Gastroenterol. 2011 May; 5(2):416-21. Epub 2011 Jul 22.
    View PubMed
  45. McHaffie DR, Kozak KR, Warner TF, Cho CS, Heiner JP, Attia S. Stewart-Treves syndrome of the lower extremity. J Clin Oncol. 2010 Jul 20; 28(21):e351-2. Epub 2010 Apr 05.
    View PubMed
  46. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR. AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol. 2010 Jun 1; 28(16):e250-1. Epub 2010 May 03.
    View PubMed
  47. Weiss JM, Attia S, Bailey HH, Weber S, Hu J, Reichelderfer M, Gopal DV. Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy. J Clin Oncol. 2010 May 20; 28(15):e233-5. Epub 2010 Apr 05.
    View PubMed
  48. Attia S, Morgan-Meadows S, Holen KD, Bailey HH, Eickhoff JC, Schelman WR, Traynor AM, Mulkerin DL, Campbell TC, McFarland TA, Huie MS, Cleary JF, Tevaarwerk AJ, Alberti DB, Wilding G, Liu G. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemother Pharmacol. 2009 Jun; 64(1):45-51. Epub 2008 Oct 08.
    View PubMed
  49. Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G. Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors. Cancer Chemother Pharmacol. 2009 Jun; 64(1):79-86. Epub 2008 Oct 22.
    View PubMed
  50. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH. Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol. 2008 Sep; 3(9):1018-25.
    View PubMed
  51. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs. 2008 Aug; 26(4):369-79. Epub 2008 Feb 16.
    View PubMed
  52. Shaw A, Attia S, Bushman W. Prostate stromal and urogenital sinus mesenchymal cell lines for investigations of stromal-epithelial interactions. Differentiation. 2008 Jul; 76(6):599-605. Epub 2008 May 07.
    View PubMed
  53. Bailey HH, Attia S, Love RR, Fass T, Chappell R, Tutsch K, Harris L, Jumonville A, Hansen R, Shapiro GR, Stewart JA. Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer. Cancer Chemother Pharmacol. 2008 Jun; 62(1):149-57. Epub 2007 Sep 21.
    View PubMed
  54. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
    View PubMed
  55. Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol. 2008 Jan; 6(1):44-54.
    View PubMed
  56. Attia S, Wilding G. Novel antioxidant technology for prostate cancer chemoprevention and treatment. Expert Opin Ther Pat. 2006 Sep; 16(9):1255-67.
    View PubMed
  57. Ajmani PS, Attia S, Osifchin M, Regen S, Hughes JA. A spermine-deoxycholic acid conjugate based lipid as a transfecting agent. Pharmazie. 1999 Mar; 54(3):191-4.
    View PubMed
  58. Attia SA, Shepherd VE, Rosenblatt MN, Davidson MK, Hughes JA. Interaction of oligodeoxynucleotides with mycobacteria: implications for new therapeutic strategies. Antisense Nucleic Acid Drug Dev. 1998 Jun; 8(3):207-14.
    View PubMed
  59. Brazeau GA, Attia S, Poxon S, Hughes JA. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery. Pharm Res. 1998 May; 15(5):680-4.
    View PubMed